Cite
MLA Citation
J.G. Robinson et al.. “Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background.” Atherosclerosis, vol. 252, 2016, pp. e231–. http://access.bl.uk/ark:/81055/vdc_100039989445.0x000010